The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership

China has the world’s second largest burden of multidrug-resistant tuberculosis (MDR-TB; resistance to at least isoniazid and rifampicin), with an estimated 57,000 cases (range, 48,000–67,000) among notified pulmonary TB patients in 2015. During October 1, 2006–June 30, 2014, China expanded MDR-TB c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lixia, Li, Renzhong, Xu, Caihong, Zhang, Hui, Ruan, Yunzhou, Chen, Mingting, Wang, Dongmei, Dirlikov, Emilio, Du, Xin, Zhao, Jin, Zhao, Yanlin, Wang, ShengFen, Liu, Yuhong, Li, Liang, Falzon, Dennis, Sun, Yanni, Wang, Yu, Schwartländer, Bernhard, Scano, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476250/
https://www.ncbi.nlm.nih.gov/pubmed/28628669
http://dx.doi.org/10.1371/journal.pone.0177536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476250/
https://www.ncbi.nlm.nih.gov/pubmed/28628669
http://dx.doi.org/10.1371/journal.pone.0177536

Ejemplares similares